<DOC>
	<DOCNO>NCT00864318</DOCNO>
	<brief_summary>Not randomize , multicentric , national phase II trial estimate efficacy intensification protocol patient refractory germ cell tumor relapse bad prognosis . Treatment consist two Paclitaxel Ifosfamide intensification cycle follow three Carboplatine Etoposide high dose cycle . The point individual Carboplatine adjustment take account inter-individual patient variability . This adaptation allow control patient plasmatic exposition avoid inacceptable toxicity ( ear toxicity ) low exposition lose benefit high dose protocol .</brief_summary>
	<brief_title>Dose Intensification Study Refractory Germ Cell Tumors With Relapse Bad Prognosis</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Germ cell tumor whatever histology ( TGNS séminoma : TGS ) whose origin gonadic , extragonadic , retroperitoneal primitive mediastinal 2 . Age &gt; = 18 year old 3 . Histologically confirm germ cell tumor ( TGS ) biomarkers rate allow diagnose germ cell tumor without histology ( TGNS ) 4 . Relapse progression bad prognosis 1st treatment line : One criterion valid point 4 : progression incomplete clinical response ( Stable disease ) Cisplatin basis chemotherapy ; biomarker progression 4 week follow last chemotherapy cycle administration ; progression first treatment line without obtention least stable disease ; primitive mediastinal origin first relapse . 5 . TGNS TGS relapse 2 treatment line 6 . Disease progression ( previous point 4 5 ) document : tumor biomarkers increase ( AFP and/or HCG ) , biopsy need confirm presence tumor active cell 7 . ECOG Performance status 02 8 . Biological Function : Neutrophils &gt; = 1500/mm3 , Platelets &gt; = 150.000/mm3 ; normal creatinine ( clearance &gt; = 50 ml/mn ) ; SGOT , SGPT &lt; = 2,5N ( 5N hepatic metastasis ) , Bilirubin &lt; 1,5N 9 . Cardiac Functions ( FEV &gt; = 50 % ) , Respiratory Functions , neurological Functions compatibles high dose chemotherapy administration 10 . Absence previous intensification 11 . Patient Information Informed consent signature 12 . HIV B C hepatitis negative serology 13 . Negative pregnancy test woman reproductive potential adequate contraception study entry 14 . Patient affiliate social security system 1 . Patients whose diagnosis relapse confirm anatomopathological examination increase tumor marker 2 . Primitive encephalic germ cell tumor 3 . Germ cell tumor relapse favorable factor treatment response conventional chemotherapy ( RC sustainable Cisplatin ) : prior cRC incomplete clinical response normalization marker testicular origin 4 . Growing Teratoma lesion 5 . Patients HIV infection , hepatitis B C 6 . Patients symptomatic brain metastasis despite appropriate corticosteroid treatment 7 . Associated pathology may prevent patient receive treatment , creatinine clearance ≤ 50 mL / min ( calculated CockcroftGault ) 8 . FEV &lt; 50 % 9 . History cancer ( except basal cell epithelioma skin cancer ) 3 year precede entry trial 10 . Patient already include another clinical trial involve experimental molecule 11 . Pregnant breast feed woman 12 . Persons without liberty guardianship , 13 . Geographical , social psychological condition permit compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>refractory</keyword>
	<keyword>germ cell tumor</keyword>
	<keyword>relapse</keyword>
	<keyword>bad prognosis</keyword>
	<keyword>Refractory germ cell tumor relapse bad prognosis</keyword>
</DOC>